01.02.2019 | Letter to the Editor
HER2 positive breast cancer patients having HER2 loss after neoadjuvant chemotherapy should still be treated with adjuvant anti-HER2 treatment
Erschienen in: Breast Cancer Research and Treatment | Ausgabe 1/2019
Einloggen, um Zugang zu erhalten